➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Moodys
Mallinckrodt
Express Scripts
Medtronic

Last Updated: April 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMMUNOGLOBULIN G

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for immunoglobulin g

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000117 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed National Eye Institute (NEI) Phase 3 1995-08-01 To determine whether high-dose intravenous immunoglobulin (IVIg) is more effective than placebo in restoring lost visual function (visual acuity) in optic neuritis (ON). To determine the time course of recovery following IVIg administration. If the reports of IVIg-associated clinical improvement occurring within 3 to 6 months following treatment can be confirmed, this would provide indirect evidence that IVIg may promote central nervous system (CNS) remyelination in optic neuritis and multiple sclerosis (MS).
NCT00000590 Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1991-09-01 To determine if HIV hyperimmune globulin (HIVIG) given to HIV-positive pregnant women during the second and third trimester of pregnancy reduced the likelihood of maternal-fetal HIV transmission. Conducted in collaboration with the National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Diseases. The trial was Pediatric ACTG Protocol 185.
NCT00000590 Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1991-09-01 To determine if HIV hyperimmune globulin (HIVIG) given to HIV-positive pregnant women during the second and third trimester of pregnancy reduced the likelihood of maternal-fetal HIV transmission. Conducted in collaboration with the National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Diseases. The trial was Pediatric ACTG Protocol 185.
NCT00000590 Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1991-09-01 To determine if HIV hyperimmune globulin (HIVIG) given to HIV-positive pregnant women during the second and third trimester of pregnancy reduced the likelihood of maternal-fetal HIV transmission. Conducted in collaboration with the National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Diseases. The trial was Pediatric ACTG Protocol 185.
NCT00000642 A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns Completed Genentech, Inc. Phase 1 1969-12-31 Part 1: To determine both the safety, tolerance, and pharmacokinetic profile (blood levels) of recombinant CD4 immunoglobulin G (rCD4-IgG) by intravenous bolus administration (given through the vein) in women with HIV infection who are in their third trimester (last three months of pregnancy). To determine the safety of maternal/fetal transfer of rCD4-IgG in infants born to mothers entered into the study. To obtain a preliminary indication of the antiviral and immunologic effects of rCD4-IgG in HIV seropositive pregnant women and their newborns. AMENDED: Part 2: To determine the safety profile of rCD4-IgG in HIV-1-infected women at the onset of labor and in their newborns. To determine the extent of placental transfer of rCD4-IgG when administered to the mother at onset of labor. To determine the pharmacokinetics of rCD4-IgG in newborns. To obtain preliminary evidence of the ability of rCD4-IgG to prevent intrapartum transmission of HIV-1 from mother to fetus. An agent that can prevent HIV infection is desirable for those at risk of infection as well as in the pregnant female and newborn populations. Such an agent may help prevent the progression of the disease in infants and children in early stages of infections. In theory, rCD4-IgG has antiviral effects.
NCT00000642 A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in HIV-1 Seropositive Women During the Last Trimester of Pregnancy and Their Newborns Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 1969-12-31 Part 1: To determine both the safety, tolerance, and pharmacokinetic profile (blood levels) of recombinant CD4 immunoglobulin G (rCD4-IgG) by intravenous bolus administration (given through the vein) in women with HIV infection who are in their third trimester (last three months of pregnancy). To determine the safety of maternal/fetal transfer of rCD4-IgG in infants born to mothers entered into the study. To obtain a preliminary indication of the antiviral and immunologic effects of rCD4-IgG in HIV seropositive pregnant women and their newborns. AMENDED: Part 2: To determine the safety profile of rCD4-IgG in HIV-1-infected women at the onset of labor and in their newborns. To determine the extent of placental transfer of rCD4-IgG when administered to the mother at onset of labor. To determine the pharmacokinetics of rCD4-IgG in newborns. To obtain preliminary evidence of the ability of rCD4-IgG to prevent intrapartum transmission of HIV-1 from mother to fetus. An agent that can prevent HIV infection is desirable for those at risk of infection as well as in the pregnant female and newborn populations. Such an agent may help prevent the progression of the disease in infants and children in early stages of infections. In theory, rCD4-IgG has antiviral effects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for immunoglobulin g

Condition Name

Condition Name for immunoglobulin g
Intervention Trials
Multiple Myeloma 25
Lymphoma 19
Leukemia 15
Asthma 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for immunoglobulin g
Intervention Trials
Lymphoma 47
Leukemia 45
Leukemia, Lymphoid 38
Multiple Myeloma 37
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for immunoglobulin g

Trials by Country

Trials by Country for immunoglobulin g
Location Trials
Canada 107
China 69
Australia 46
United Kingdom 39
France 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for immunoglobulin g
Location Trials
California 91
New York 68
Maryland 64
Texas 61
Ohio 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for immunoglobulin g

Clinical Trial Phase

Clinical Trial Phase for immunoglobulin g
Clinical Trial Phase Trials
Phase 4 75
Phase 3 140
Phase 2/Phase 3 30
[disabled in preview] 377
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for immunoglobulin g
Clinical Trial Phase Trials
Completed 234
Recruiting 162
Not yet recruiting 157
[disabled in preview] 120
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for immunoglobulin g

Sponsor Name

Sponsor Name for immunoglobulin g
Sponsor Trials
National Cancer Institute (NCI) 67
National Institute of Allergy and Infectious Diseases (NIAID) 23
Mayo Clinic 19
[disabled in preview] 53
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for immunoglobulin g
Sponsor Trials
Other 747
Industry 329
NIH 117
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKinsey
Dow
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.